ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ADC Therapeutics posts robust Q4 results, eyes pipeline expansion

ADC Therapeutics delivered strong financial results, bolstered by Zynlonta's sales growth and a healthy cash position.
Strategic decisions on pipeline programs and market access initiatives demonstrate a focus on long-term growth and profitability.
While facing challenges such as market access delays and community adoption hurdles, ADC Therapeutics remains poised for success with multiple growth opportunities ahead.

ADC Therapeutics accelerates pipeline progress and optimizes ZYNLONTA's potential

ADC Therapeutics is making strides in pipeline prioritization and operational efficiencies, focusing on ZYNLONTA's commercial success.
The company faces challenges in navigating market dynamics and implementing strategic changes while capitalizing on growth opportunities.
Opportunities lie in expanding trial sites, exploring potent combinations, and leveraging the new go-to-market model for enhanced performance.
Overall, ADC Therapeutics aims for sustained growth through strategic resource allocation and operational enhancements.

ADC Therapeutics reports revenue growth and strategic expansions in Q2

ADC Therapeutics showcased solid Q2 performance with revenue growth and strategic expansions.
While facing challenges in clinical trials and market dynamics, the company is leveraging strengths in portfolio investments and market positioning.
Opportunities lie in upcoming milestones, international expansions, and innovative sales strategies for sustained growth.

ADC Therapeutics reports mixed Q3 results, positive pipeline outlook

ADC Therapeutics faced challenges in ZYNLONTA sales but showcased positive pipeline updates and promising Cami trial results.
Management's focus on cost control and cash preservation aligns with maintaining financial stability until mid-2025.
Analysts' inquiries into commercial strategies and regulatory timelines reflect market interest and potential growth opportunities.
Overall, ADCT's performance highlights a mix of challenges, strengths, and opportunities in navigating the competitive landscape.

ADC Therapeutics reports robust earnings, eyes expansion in oncology market

ADC Therapeutics demonstrated strong financial performance and progress in clinical trials, positioning itself well for future growth. Strategic focus on key pipelines and real-world data strategies highlight a commitment to innovation.
While facing competition and evolving treatment landscapes, the company has opportunities to expand ZYNLONTA and leverage next-gen platforms. Ongoing partnership discussions and upcoming trial results offer avenues for advancement.
Challenges include market differentiation, safety data focus, and successful trial enrollment. Managing these hurdles while capitalizing on growth opportunities will be crucial for ADC Therapeutics' future success.

ADCT reports revenue growth and strategic advancements in Q1

ADCT's Q1 performance reflects revenue growth, cost management, and strategic investments in pipeline development and financial stability.
Strengths lie in ZYNLONTA's performance, successful fundraising, disciplined capital allocation, and diversified pipeline progress.
Challenges include market competition, net losses, regulatory considerations, and balancing expenses with revenue growth.
Opportunities arise from expanding into new indications, advancing therapeutic candidates, regulatory engagements, and solid tumor pipeline growth.

ADC Therapeutics achieves profitability driven by ZYNLONTA in hematology

ADC Therapeutics demonstrated strong financial performance with commercial profitability and cost management improvements.
The company's focus on hematology and advancements in product pipeline position them for future growth.
While facing challenges in sales variability and market competition, ADC Therapeutics has opportunities for expansion and differentiation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ADC Therapeutics SA (NYSE:ADCT ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Amanda Hamilton - IR Manager Ameet Mallik - CEO Joe Camardo - Chief Medical Officer Jenn Creel - CFO Conference Call Participants Gregory Renza - RBC Brian Cheng - JPMorgan Boris Peaker - Cowen Kelly Shi - Jefferies Operator Welcome to the ADC Therapeutics Third Quarter 2022 Financial Results Conference Call. My name is Kevin, and I'll be your operator for today's call.

ADC Therapeutics SA (ADCT) Q3 2022 Earnings Call Transcript

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -27.45% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the third quarter ended September 30, 2022 and provided business updates.

ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on several of its antibody drug conjugates (ADCs), including ZYNLONTA® (loncastuximab tesirine-lpyl), camidanlumab tesirine (Cami) and ADCT-602, will be presented at the 64th American Society of Hematology (ASH) Annual Meeting, which will be held in New Orleans, Louisiana from December 10-13, 2022.

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting

IGM Biosciences Inc

IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Kristen Harrington-Smith as Chief Commercial Officer, effective November 17, 2022.

ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m.

ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022

The heavy selling pressure might have exhausted for ADC Therapeutics SA (ADCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 27.9% in 4 Weeks, Here's Why You Should You Buy the Dip in ADC Therapeutics SA (ADCT)

ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 28.5% in 4 Weeks, Here's Why ADC Therapeutics SA (ADCT) Looks Ripe for a Turnaround

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that ZYNLONTA® (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022), which will be held in Houston, Texas from September 28–October 1, 2022. “We are looking forward to sharing the encouraging initial safety run-in results from our LOTIS-5 Phase 3 clinical trial evaluating ZY

ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)

New York, New York--(Newsfile Corp. - September 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether ADC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA - ADCT

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of ZYNLONTA® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The positive opinion from the CHMP is now referred to the European Commission for an a

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

LOS ANGELES--(BUSINESS WIRE)---- $ADCT #ADCT--The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley's 20th Annual Global Healthcare Conference on Tuesday, September 13th at 11:45 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of the webcast will be available for approx

ADC Therapeutics to Participate in Morgan Stanley's 20th Annual Global Healthcare Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that it has completed a series of strategic transactions in which it: Entered into a new $175 million senior secured term loan with certain funds of Owl Rock, a division of Blue Owl Capital, Inc. (“Owl Rock”), and funds managed by Oaktree Capital Management, L.P. (“Oaktree”) with an upfront tranche of $120 million received upon closing today; Settled in full the $115 million aggregate principal amount of se

ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes

ADC Therapeutics SA (NYSE:ADCT ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Amanda Hamilton - IR Manager Ameet Mallik - CEO Jennifer Herron - Chief Commercial Officer Jenn Creel - CFO Joe Camardo - Chief Medical Officer Conference Call Participants Kelly Shi - Jefferies Gregory Renza - RBC Boris Peaker - Cowen Operator Welcome to the ADC Therapeutics Second Quarter 2022 Financial Results Conference Call. My name is Gigi, and I'll be your operator for today's call.

ADC Therapeutics SA (ADCT) CEO Ameet Mallik on Q2 2022 Results - Earnings Call Transcript

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2022 and provided business updates. “The ZYNLONTA® launch is advancing steadily as we continue to increase awareness and advocacy. There is significant opportunity ahead and we have a focused plan in place to achieve continued growth in the coming quarters,” commented Ameet Mallik, Chief Executive Officer of ADC Therapeutics. “Our pipeline of hematology

ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET to report financial results for the second quarter 2022 and provide business updates. To access the conference call, please register here. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcas

ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced the first patient has been dosed in the Phase 1b clinical trial evaluating ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and in combination with gemcitabine in patients with selected advanced solid tumors. “We look forward to the continued evaluation of ADCT-601, our AXL-targeting ADC, in advanced solid tumors after having established a manageable tolerability profile in our Phase 1a dos

ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors

ADC Therapeutics SA (ADCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADC Therapeutics SA (ADCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced the first patient has been dosed in LOTIS-9, a Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab (Lonca-R) in unfit and frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL). “Unfit, elderly, and frail DLBCL patients represent a growing population for which new treatments are greatly needed. These patients are often unable to tol

ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma

BOSTON & SHANGHAI & LAUSANNE, Switzerland--(BUSINESS WIRE)--Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals (“Overland”) and ADC Therapeutics SA (NYSE: ADCT), today announced the first patient has been dosed in China with ZYNLONTA® in combination with rituximab compared to standard immunochemotherapy in the LOTIS-5 confirmatory Phase 3 global clinical trial in second-line or later, transplant ineligible patients with diffuse large B-cell lymphoma (DLBCL). In April 2

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial

Agreement augments Sobi's strategic presence in haematology with new orphan medicine STOCKHOLM , July 8, 2022 /PRNewswire/ -- Sobi® today announced an exclusive license agreement with ADC Therapeutics SA to develop and commercialise loncastuximab tesirine for use in haematology and other indications of large unmet medical need in Europe and most international markets. Loncastuximab tesirine is an antibody-drug conjugate (ADC) against CD19, a protein expressed on the surface of B cells.

Sobi to license loncastuximab tesirine from ADC Therapeutics

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan. The Marketing Authorization Application (MAA) for ZYNLONTA was validated by the European Medicines Agency (EMA) at the end of October 2021, and orpha

ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories

News for ADC Therapeutics Stock (ADCT)